Department of Pathology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA.
Diagn Pathol. 2008 Jul 1;3:28. doi: 10.1186/1746-1596-3-28.
A variety of novel endometrial ablation technologies are now in routine use. A subset of uteri that had previously undergone these treatments will ultimately be evaluated by the pathologist. However, the full spectrum of histologic changes that may result from these treatments has received only sporadic attention. The NovaSure [Hologic Corporation, Marlborough, MA, USA] endometrial ablation system is one of several available second-generation technologies and its particular endometrial ablative power is based on the delivery of radiofrequency energy. The present analysis was designed to decipher any histologic changes (if any) associated with the NovaSure endometrial ablation system relative to benign smooth muscle tumors of the uterine corpus. Over a one-year period, 3 uteri that had previously undergone the NovaSure endometrial ablation and which also had leiomyomatous mass lesions were evaluated. The leiomyomatous mass lesions were extensively sampled and were evaluated for cellular shapes (epithelioid change, cellular rounding, extraordinary cytoplasmic eosinophilia, clear cell change, cytoplasmic vacuolation), nuclear changes (nucleomegaly, nucleolomegaly, multinucleation, hyperchromasia, symplastic changes), necrosis (coagulative and/or infarct), mitotic activity, apoptotic bodies or pyknotic cells, myxoid change, hyalinization. The three uteri were resected 61, 47 and 74 (mean 60.7) days post-ablation. After a detailed evaluation of multiple submucosal, intramural and subserosal leiomyomata from these 3 uteri, no noteworthy histologic changes were identified in the tumors. Since the presence or absence of tumor necrosis is one histologic criterion by which malignant potential is assigned to uterine smooth muscle neoplasms, defining any extrinsic processes that may establish, or contribute to this finding is clinically relevant. The findings reported herein suggests that if a leiomyoma that was obtained from a patient that had recently undergone the NovaSure endometrial ablation displays any degenerative changes such as necrosis, the changes are probably not attributable to the ablation.
现在有多种新型的子宫内膜消融技术在常规使用。以前接受过这些治疗的一部分子宫最终将由病理学家进行评估。然而,这些治疗可能导致的全部组织学变化仅受到零星关注。NovaSure [Hologic Corporation,马萨诸塞州马尔伯勒,美国]子宫内膜消融系统是几种可用的第二代技术之一,其特殊的子宫内膜消融能力基于射频能量的传递。本分析旨在破译与 NovaSure 子宫内膜消融系统相关的任何组织学变化(如果有),相对于子宫体的良性平滑肌肿瘤。在一年的时间里,评估了 3 个以前接受过 NovaSure 子宫内膜消融且有平滑肌瘤肿块病变的子宫。对平滑肌瘤肿块进行了广泛采样,并评估了细胞形状(上皮样变化、细胞圆形化、异常细胞质嗜酸性、透明细胞变化、细胞质空泡化)、核变化(核肥大、核肥大、多核、嗜碱性、合胞体变化)、坏死(凝固性和/或梗死)、有丝分裂活性、凋亡小体或固缩细胞、黏液样变、玻璃样变。这 3 个子宫在消融后 61、47 和 74(平均 60.7)天被切除。对这 3 个子宫的多个黏膜下、壁内和浆膜下平滑肌瘤进行详细评估后,在肿瘤中未发现明显的组织学变化。由于肿瘤坏死的存在与否是评估子宫平滑肌肿瘤恶性潜能的一个组织学标准,因此确定可能导致或有助于这一发现的任何外在过程在临床上是相关的。本报告的研究结果表明,如果从最近接受过 NovaSure 子宫内膜消融的患者中获得的平滑肌瘤显示出任何退行性变化,如坏死,则这些变化可能不是由消融引起的。